Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $16.14 -3.06%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Bloom Burton & Co. analyst David Martin upgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) from Hold (3) to Buy (1) with a price target of $21.00.
For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.
Shares of Aurinia Pharmaceuticals closed at $16.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Downgrades Marvell (MRVL) to Neutral
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
- Sinda Ltd. (SIND) Reports Q3 Loss of $0.10
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
